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Abstract 
Veterinary vaccines must be safe, pure, potent, and effective. Potency tests help ensure that each consistently manufactured batch 
of vaccine provides a level of protection as determined in the original efficacy study throughout the products shelf life. Currently 
approved assays range from host animal vaccination and challenge to the quantification of specific protective antigens using in 
vitro technology. The development, maintenance, and update of in vitro potency assays continue to be a priority for both the 
animal health industry and the corresponding regulatory agencies. New assay development emphasis is being placed on assays 
that currently involve laboratory animal vaccination/challenge such as vaccines containing the Leptospira and Clostridium spp. 
antigens. This paper provides an overview of various in vitro potency assays available, the factors that can impact the accuracy of 
these methods, and specific considerations to be taken into account during assay development. 
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1. Introduction 
Veterinary vaccines must be safe, pure, potent, and effective. These four attributes serve to build the framework 
for current regulations on a global basis. Vaccine effectiveness is demonstrated in the host animal immunogenicity 
studies used to support product registration. These studies establish the minimum antigenic dose known to elicit a 
statistically significant, clinically relevant protective effect. To be eligible for use, each batch of vaccine released for 
distribution must meet or exceed this level of efficacy and maintain it through its shelf life. The potency assay is 
used to establish this link and must therefore be correlated to efficacy. 
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Veterinary vaccines can be divided into two large groups: (1) those that contain live presentations of the 
immunizing antigen and (2) those that contain an inactivated presentation. Antigens may be the whole virus or 
bacteria and may be prepared with limited purification. Antigens may also be partially purified preparations, either 
natural or genetically engineered, or purified peptides. Most inactivated vaccines, and increasingly some live 
vaccines, also contain one or more adjuvants to boost the immune response. In many cases, particularly with 
bacterial vaccines, the protective epitope is either unknown or is a combination of antigenic proteins. As an 
additional complication, most veterinary vaccines are sold as large combination vaccines that include multiple 
antigens. All of these factors contribute to the difficulty of developing and validating in vitro potency assays or 
refining current assays to reduce the use of animals. 
2. Types of potency assays 
Historically, potency for most animal health vaccines was demonstrated by means of vaccination and subsequent 
challenge of the vaccinates with the live pathogenic agent. The challenge tests used laboratory animals (including 
mice, hamsters, and guinea pigs) and often the host animal. Several current vaccines still require these in vivo 
assays, with the most notable including rabies vaccines, Clostridial and Leptospira-containing vaccines, fish 
vaccines, and certain poultry products. For many vaccines containing live antigens, these tests have been largely 
replaced by in vitro assays that titrate the live antigen content in the vaccines [1]. In other cases, in vitro serologic 
assays have been developed that measure the vaccinated animal’s immune response to antigens that have been 
demonstrated to correlate to efficacy, thereby avoiding the challenge test. Enzyme-linked immunosorbent assay 
(ELISA) technology has been developed for inactivated products. These ELISAs are based on the in vitro 
quantification of antigens known to be protective in the host. Many of these assays are designed as relative potency 
assays, in which the potency of the unknown vaccine is compared to a “reference” vaccine that has previously been 
demonstrated as effective in the host animal. Figure 1 illustrates an approximation of the percentage of veterinary 
vaccine potency assays that fall into the various groupings described [2]. 
 
 
For the determination of live viral antigen concentration, a microtiter plate cell culture system is often employed, 
utilizing tissue culture (50% tissue culture infective dose [TCID50]), fluorescent antibody (50% fluorescent antibody 
infectious dose [FAID50]), or plaque-forming units (PFU) as the endpoint. The assay often uses the methods of Reed 
and Muench or Spearman Karber for quantification [3, 4]. The assay is correlated to the protective dose 
demonstrated in the host animal immunogenicity study and frequently includes an overage to allow for testing error 
Figure 1. Estimated usage of potency assays for USDA licensed non-poultry non-aquaculture vaccines [1] 
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and loss during storage (in the U.S., 100.7 and approximately 100.5 TCID50/dose, respectively). The potency of live 
bacterial vaccines is usually expressed as colony-forming units or CFU. Particle counts can also be used for live 
bacterial vaccines, but the assay must be designed to differentiate between living and dead microorganisms. Live-
vectored recombinant antigens can be quantified using a live antigen titration method similar to those described 
above; however, in these cases an assay for expression of the inserted gene must be included as part of the potency 
assay. A significant advantage of live antigen titration methods to determine potency is that the same assay can be 
used for the determination of antigen content at the time of vaccine assembly and for the final product assay, a 
somewhat difficult task with inactivated vaccines. 
The vaccination of either the target animal or a suitable laboratory animal has historically been viewed as a 
primary option for potency assays. This is particularly true for inactivated vaccines, in which titration of the live 
antigen is no longer an option. Animal welfare considerations, cost, assay duration, and assay variability have all 
been drivers for the animal health industry to find alternative assays. There is still, however, a number of products 
for which vaccination, followed by challenge, remains the primary assay (rabies vaccines, Leptospira-containing 
products, many Clostridial vaccines, most fish vaccines, and certain poultry products). A benefit of in vivo assays is 
that the role of the adjuvant in the immune response is directly measured by the assay. 
As an alternative to challenge, serology can sometimes be used as an indicator of potency. For serology to be an 
effective tool, the antibody response to the test vaccine antigen must be the primary protective response in the 
vaccinated host. As with a potency assay that relies on vaccination challenge, serologic assays also take into account 
the adjuvant’s role in the final formulation. In some cases, a second animal species, often mice, is used as a measure 
of post-vaccination serologic response. Many of the Clostridial products involve the vaccination of rabbits, followed 
by the use of mice to titrate the antitoxin response generated by the Clostridial toxoid using a lethal toxin challenge. 
The animal health industry has made significant progress over the last 20 years in developing in vitro potency 
assays for inactivated antigens. These in vitro assays involve the direct measure of antigen in a vaccine using 
methods such as hemaglutination, and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). For 
certain peptide vaccines, high-pressure liquid chromatography (HPLC) or the use of immunologic methods such as 
immuno diffusion (RID, rocket) or ELISAs may be used. To provide a correlation to efficacy in the host, many of 
the assays involve the direct comparison of the test vaccine to a reference vaccine that was initially tested for 
efficacy in the host animal. These assays are referred to as relative potency (RP) assays; they currently form the 
majority of in vitro assays employed by the industry. Because these assays do not measure the role of adjuvant in the 
immune response, some regulatory agencies require a second assay to measure the adjuvant, e.g., total aluminum 
content in alum-adjuvanted vaccines. 
3. Considerations for developing in vitro potency assays  
Of primary concern in developing an in vitro assay is the identification of appropriate target antigens(s) for the 
assay. The ideal assays measure a protective immunogen or immunogens through the use of the following: 
• Purified proteins that elicit protection in vaccinated animals 
• Antibodies to proteins that neutralize the infectivity of the agent in an in vitro assay 
• Monoclonal antibodies to the protein that passively protect animals against challenge 
Additional considerations in developing appropriate in vitro assays include the correlation of the assay to host 
animal efficacy; assay interference by the adjuvant(s), other antigens, and/or vaccine components; accuracy, 
precision, and the sensitivity of the assay; and the demonstration of reference stability over time. 
The majority of animal health inactivated vaccines are adjuvanted, raising two additional concerns: assay 
interference and the immunological impact of the adjuvant in the product specifications. Assay interference 
attributable to adjuvants can include the direct interference of the adjuvant on the assay (e.g., high background, 
nonparallelism) and the impact caused by the direct binding of the antigen to the adjuvant. As industry moves 
toward the increased use of in vitro assays, regulators in certain regions have been concerned with assessing the 
impact of the adjuvant on serial potency. This can be accomplished through a variety of physical and chemical 
assays, including particle sizing, aluminum concentration, and HPLC, and through the use of tightly controlled 
(Good Manufacturing Practice [GMP]) production systems and component specifications. However, this will likely 
require development and validation of additional assays by industry. 
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In vitro relative potency assays have additional requirements that need to be factored into assay development. In 
these assays, the reference vaccine serves as “the stake in the ground” linking the assay to host animal efficacy. In 
order for this to be valid, the relationship between the dose-response curves of the reference with that of 
representative vaccine serials must be evaluated; and parallelism must be demonstrated through the linear region 
that encompasses the critical assay range. Because the reference is the key indicator of efficacy, stability of the 
reference needs to be understood and demonstrated, and plans must be established to qualify a new reference 
preparation as needed. 
The recently developed Leptospira vaccine assays serve an as example of the progress made by the U.S. 
Department of Agriculture (USDA) and industry in moving toward ELISA test methods, but they also illustrate 
some of the potential concerns. The Leptospira vaccines are commonly used across multiple species, including 
canine, bovine, and porcine, and are complex combination vaccines that include multiple Leptospira serovars and 
often other antigens. The current in vivo Leptospira potency assay involves a hamster vaccination / challenge assay. 
This is a lethal endpoint challenge assay and includes testing for each of the multiple serovars of Leptospira 
contained in the product. The test is time consuming, involving a period of 5+ weeks. Because the Leptospira are 
zoonotic, the assay also involves a significant exposure risk to laboratory and animal care personnel. To address 
these issues, USDA personnel have developed a sandwich ELISA potency test that uses a polyclonal rabbit capture 
antibody and specific mouse monoclonal detecting antibodies. Supplemental Assay Methods (SAM Nos. 624-627 
[5]) have been published, and U.S. veterinary biological manufacturers are in the process of adopting these assays. 
Hurdles that remain to be overcome include addressing potential assay interference due to the various adjuvant 
formulations used by the industry and interference caused by other antigens and components of the various vaccines. 
4. Other new potential in vitro assay technologies 
The use of the quantitative polymerase chain reaction (qPCR) assay has been proposed as an alternative potency 
assay due to its ability to determine the number of organisms based on the nucleic assay copy number. However 
since the qPCR assay does not measure either the expression or conformation of the target antigen, its use is limited 
to a potential supportive assay in combination with another assay. HPLC has shown promise as an additional 
potential assay method for use in the quantification of the new purified peptide or subunit vaccines. The use of cell 
culture toxicity as a replacement for the mouse in clostridial antitoxin determination has also been proposed [6]. 
5. Conclusion 
Significant progress has been made in the development, maintenance, and update of in vitro potency assays, and 
this continues to be a priority for the animal health industry and the regulatory agencies. New assay development 
emphasizes assays that currently involve laboratory animal vaccination/challenge, such as vaccines containing the 
rabies, Leptospira, and Clostridium spp. antigens.  
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